About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Modeling the burden of abdominal aortic aneurysm (AAA) in Europe in 2013


To estimate the number of prevalent cases of abdominal aortic aneurysm (AAA)and deaths attributable to AAA in five major European Union (5EU) markets:France, Germany, Italy, Spain, and the United Kingdom (UK).


We used disease modeling software, DisMod II (World Health Organization), toassess AAA burden via a multi-state life table where differential equationsdefine relationships between incidence, prevalence, and disease-specificmortality. Market-specific input data included age- and sex-specific populationstructure, age- and sex-specific all-cause mortality, and cubic splineinterpolation of size- and sex-specific AAA prevalence. Other input dataconsisted of relative risk (RR) estimates of death for persons with AAAcompared with persons without AAA, adjusted for age, ethnicity, height, weight,smoking, and cardiovascular disease history.


We estimated 2,484,058 prevalent cases in the 5EU in 2013 (90% CI:2,282,702–2,638,106), resulting in 48,805 deaths attributable to AAA (90% CI:39,924–54,291). In the combined 5EU, females accounted for 20.2% of prevalentcases and 43.2% of deaths. France had the lowest number of prevalent cases(581.8 per 100,000 population) and deaths (11.0 per 100,000 population) amongthe 5EU markets, while Italy had the highest number of prevalent cases (1,103.7per 100,000 population) and deaths (22.3 per 100,000 population). The number ofdeaths attributable to AAA in Italy represented 28.0% of the 5EU total, despiteItaly accounting for only 19.3% of the 5EU population in 2013.


Our study reveals that the burden of AAA among the 5EU markets is most severein Italy, which accounted for the highest number of both prevalent cases anddeaths attributable to AAA in the 5EU. Throughout the 5EU, females accountedfor a disproportionately high percentage of deaths despite constituting a lowpercentage of prevalent cases. Consequently, current screening guidelinesshould target both sexes, rather than males only.